Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia

NCT01338337 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndrome (MDS)

Interventions

DRUG: Azacitidine

Sponsor

Asociación Andaluza de Hematología y Hemoterapia